Bevacizumab for Cancer

Phase-Based Progress Estimates
University of Texas MD Anderson Cancer Center, Houston, TX
Cancer+1 More
Bevacizumab - Drug
Any Age
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a drug combination can be given to patients with advanced cancer.

See full description

Eligible Conditions

  • Cancer
  • Cancer, Advanced

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether Bevacizumab will improve 1 primary outcome and 1 secondary outcome in patients with Cancer. Measurement will happen over the course of Continuous assessment during each dose level/28-day cycle.

Day 28
Antitumor Efficacy of the Combination of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone in Advanced or Metastatic Cancer That is Refractory to Standard Treatment
Continuous assessment during each dose level/28-day cycle
Maximum Tolerated Dose (MTD) of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone in Advanced or Metastatic Cancer That is Refractory to Standard Treatment

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

1 Treatment Group

Dasatinib, Bevacizumab + Paclitaxel
1 of 1
Experimental Treatment

This trial requires 218 total participants across 1 different treatment group

This trial involves a single treatment. Bevacizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Dasatinib, Bevacizumab + PaclitaxelDose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15 Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation.
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days after the last dose of study drugs
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 28 days after the last dose of study drugs for reporting.

Closest Location

University of Texas MD Anderson Cancer Center - Houston, TX

Eligibility Criteria

This trial is for patients born any sex of any age. You must have received 1 prior treatment for Cancer or the other condition listed above. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months.
Patients must be >/= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment providing radiation is not delivered to the only site of disease being treated under this protocol. After targeted/biologic therapy a patient has to be off treatment for 5 half-lives or 3 weeks whatever is shorter.
ECOG performance status </= 2.
Patients must have normal organ and marrow function defined as: absolute neutrophil count >/= 1,000/mL; platelets >/=90,000/mL; creatinine </= 2 X ULN; total bilirubin </= 2.0; ALT(SGPT) </= 5 X ULN; Exception for patients with liver metastasis: total bilirubin </= 3 x ULN; ALT(SGPT) </= 8 X ULN.
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose.
Patients must be able to understand and be willing to sign a written informed consent document.

Patient Q&A Section

How many people get cancer a year in the United States?

"Around 1.2 million people will be diagnosed with a form of cancer in the United States this year. Around 200,000 people will die, and this number will increase. Around 80% will be diagnosed with a form of cancer related to smoking. Around 65% will be diagnosed with breast cancer, and around 30% will be diagnosed with lung cancer. Around 80% will be diagnosed with cancer related to tobacco. Between 30% and 50% will die from cancer. Diabetes is affecting 3 million people, and this number is expected to double over the next 20 years. Around 1.2 million American children will be diagnosed with cancer in the year 2002. Most children will live to be 80 years or older." - Anonymous Online Contributor

Unverified Answer

Can cancer be cured?

"The first cancer cure is not yet on the way. But progress has been made with chemotherapy and radiation therapy. More importantly, most malignancies are now curable by these more aggressive approaches to treatment rather than relying on alternative or complementary approaches. However, a cure for cancer is still a long way ahead." - Anonymous Online Contributor

Unverified Answer

What are common treatments for cancer?

"Common treatments of cancer include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. There is no cure for cancer. Treatment must be tailored to the tumor type and the patient's overall health." - Anonymous Online Contributor

Unverified Answer

What causes cancer?

"Most cancers are caused in one of several ways, which can be grouped into six main causes for common cancers in adults, namely infections, dietary deficiency deficiencies, pollution, tobacco smoking, excessive use of alcohol and drug misuse. The main causes for many of the diseases are quite complex and include many other factors such as genetics and the environment in which a person lives." - Anonymous Online Contributor

Unverified Answer

What is cancer?

"Cancer is an abnormal growth of cells in the body which reproduce itself but do not die. More than 100,000 people are diagnosed with cancer each year in the UK.\n" - Anonymous Online Contributor

Unverified Answer

What are the signs of cancer?

"Skin changes were mostly skin nodules, and may be a sign of cancer or any cutaneous irritation. The signs of cancer are usually limited to localized or localized metastatic lesions, that can be palpated, palpated, or detected through imaging or through laboratory tests and not necessarily by physical examination of the body surface." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of bevacizumab?

"There is growing awareness that bevacizumab may trigger dermatologic reactions in 10-30% of patients undergoing it. Allergic reactions involving the skin are the most common, but rarely severe (e.g. angioedema, blistering, anaphylaxis). Most commonly seen dermatologic events were pruritic erythema and folliculitis. Most patients had only one dermatologic event (primarily pruritus), and all events occurred within 90 days of initiating bevacizumab treatment. Only 6% of patients complained of itching, the least common event. A causal relationship between the drug and the dermatologic symptoms is unclear." - Anonymous Online Contributor

Unverified Answer

Is bevacizumab safe for people?

"Adverse effects with and without treatment were manageable with either observation or topical corticosteroids. Treatment may enhance the risk of thrombocytopenia and may increase the risk of hypersensitivity reactions when compared with observation only. The safety and acceptable risks of bevacizumab therapy in this population appears to be similar to what has been shown in the treatment of non-curative malignancies." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for cancer?

"This preliminary study identified potential candidates/contraindications for enrollment into cancer clinical trials, highlighting the need for a standard checklist to help clinicians identify patients who are/are not eligible for clinical trials. Such a checklist could also help clinicians determine which patients have the highest likelihood of benefit from clinical trial enrollment." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of cancer?

"Primary cancer causes are not things like smoking and air pollution like these cause lung cancer specifically, they may include things such as viruses, bacteria, and so on. They are also not things like alcohol like this can cause a type of cancer, most people in this situation would probably do better with a primary prevention approach to get their cancer under control, not just dealing with it after it has happened." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in bevacizumab for therapeutic use?

"Recently a large trial of bevacizumab with a large number of patients has been published showing a benefit in metastatic disease. This is the first large study of bevacizumab therapy in patients with metastatic disease. Although this study was not randomized, it showed some strong evidence suggesting that bevacizumab may be a useful treatment. However, in patients at high risk of death it should be used with skepticism. Other ongoing clinical trials are comparing bevacizumab to placebo in the metastatic setting." - Anonymous Online Contributor

Unverified Answer

What is the latest research for cancer?

"The incidence of cancer in England and Wales and Northern Ireland has continued to rise as of the year, which is projected to increase, there have been no significant decreases in mortality rates. Currently available methods for diagnosing cancer with any degree of certainty will continue to advance. In addition, the ability to accurately categorise the patient in terms of cancer type, grade, and treatment response will be made easier." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.